SYNCOM FORMULATIONS (INDIA)
Back to Balance Sheet
|
SYNCOM FORMULATIONS (INDIA) Last 5 Year Total Current Liabilities History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2017 | |
|---|---|---|---|---|---|
| Total Current Liabilities | ₹62 Cr | ₹109 Cr | ₹113 Cr | ₹78 Cr | ₹59 Cr |
What is the latest Total Current Liabilities ratio of SYNCOM FORMULATIONS (INDIA) ?
| Year | Total Current Liabilities |
|---|---|
| Mar2025 | ₹62 Cr |
| Mar2024 | ₹109 Cr |
| Mar2023 | ₹113 Cr |
| Mar2022 | ₹78 Cr |
| Mar2017 | ₹59 Cr |
How is Total Current Liabilities of SYNCOM FORMULATIONS (INDIA) Trending?
| Years | Total Current Liabilities | % Change | |
|---|---|---|---|
| Mar2025 | ₹62 Cr | -43.19 | |
| Mar2024 | ₹109 Cr | -3.89 | |
| Mar2023 | ₹113 Cr | 44.60 | |
| Mar2022 | ₹78 Cr | 33.01 | |
| Mar2017 | ₹59 Cr | - | |
Compare Total Current Liabilities of peers of SYNCOM FORMULATIONS (INDIA)
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| SYNCOM FORMULATIONS (INDIA) | ₹1,881.9 Cr | 2.6% | 30.4% | 4.6% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹440,398.0 Cr | -0.4% | -3.3% | 15.5% | Stock Analytics | |
| DIVIS LABORATORIES | ₹250,390.0 Cr | 0.4% | 9.9% | 55.1% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹182,738.0 Cr | -3.4% | -4.2% | 37.1% | Stock Analytics | |
| CIPLA | ₹111,888.0 Cr | 0.5% | -3.2% | -12.8% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹100,329.0 Cr | 0.9% | 0% | -11% | Stock Analytics | |
SYNCOM FORMULATIONS (INDIA) Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| SYNCOM FORMULATIONS (INDIA) | 2.6% |
30.4% |
4.6% |
| SENSEX | -0.8% |
-3.8% |
-8.9% |
You may also like the below Video Courses